{"transactions":[{"id":4634547,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-10-01T00:33:24.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":642,"price":58.4055,"value":37496.331,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the Reporting Person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":79823,"source":{"system":"sec-edgar","filing":"0001683607-26-000016","document":"wk-form4_1790800401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000168360726000016/wk-form4_1790800401.xml","form_type":"4"}},{"id":722824,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-06-30T21:15:17.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":689,"price":54.3998,"value":37481.4622,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":79181,"source":{"system":"sec-edgar","filing":"0001683607-26-000014","document":"wk-form4_1782854114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000168360726000014/wk-form4_1782854114.xml","form_type":"4"}},{"id":746321,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-06-08T20:20:18.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4545,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":78492,"source":{"system":"sec-edgar","filing":"0001683607-26-000012","document":"wk-form4_1780950015.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000168360726000012/wk-form4_1780950015.xml","form_type":"4"}},{"id":824199,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-03-31T20:09:28.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":815,"price":45.977,"value":37471.255,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":73947,"source":{"system":"sec-edgar","filing":"0001683607-26-000010","document":"wk-form4_1774987765.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000168360726000010/wk-form4_1774987765.xml","form_type":"4"}},{"id":943671,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-01-08T21:03:19.000Z","date":"2026-01-07","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant."}],"balance_after":2861,"derivative":{"exercise_price":374.12,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001683607-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168360726000008/edgardoc.xml","form_type":"4"}},{"id":943670,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-08T21:03:19.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":800,"value":1200000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 1,500 shares of Company stock on January 7, 2026 at prices ranging from $800.00 to $800.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 7, 2026 at each separate price."}],"balance_after":1703,"source":{"system":"sec-edgar","filing":"0001683607-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168360726000008/edgardoc.xml","form_type":"4"}},{"id":943669,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-08T21:03:19.000Z","date":"2026-01-07","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":374.12,"value":561180.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025."}],"balance_after":3203,"source":{"system":"sec-edgar","filing":"0001683607-26-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168360726000008/edgardoc.xml","form_type":"4"}},{"id":944525,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:19:06.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":21.31,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":11100},"source":{"system":"sec-edgar","filing":"0001683607-26-000006","document":"wk-form4_1767835143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1683607/000168360726000006/wk-form4_1767835143.xml","form_type":"4"}},{"id":944524,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:19:06.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":22.81,"expiration_date":"2034-12-16","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001683607-26-000006","document":"wk-form4_1767835143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1683607/000168360726000006/wk-form4_1767835143.xml","form_type":"4"}},{"id":944523,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:19:06.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":12.64,"expiration_date":"2034-07-17","underlying":"Common Stock","underlying_shares":2125},"source":{"system":"sec-edgar","filing":"0001683607-26-000006","document":"wk-form4_1767835143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1683607/000168360726000006/wk-form4_1767835143.xml","form_type":"4"}},{"id":944522,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:19:06.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2125,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":23.4,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":2125},"source":{"system":"sec-edgar","filing":"0001683607-26-000006","document":"wk-form4_1767835143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1683607/000168360726000006/wk-form4_1767835143.xml","form_type":"4"}},{"id":944521,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:19:06.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":10.6,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":1400},"source":{"system":"sec-edgar","filing":"0001683607-26-000006","document":"wk-form4_1767835143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683607/000168360726000006/wk-form4_1767835143.xml","form_type":"4"}},{"id":944520,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:19:06.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":875,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":38.4,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":875},"source":{"system":"sec-edgar","filing":"0001683607-26-000006","document":"wk-form4_1767835143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683607/000168360726000006/wk-form4_1767835143.xml","form_type":"4"}},{"id":944519,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T01:19:06.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":50.2,"expiration_date":"2031-01-21","underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001683607-26-000006","document":"wk-form4_1767835143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683607/000168360726000006/wk-form4_1767835143.xml","form_type":"4"}},{"id":944518,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-08T01:19:06.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15,"price":221.5,"value":3322.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a \"Series A Share\"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\"). [continues to Footnote 2]"},{"field":"kind","element":"transactionCoding","label":"F2","text":"[continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the \"Common Share Merger Consideration\"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the \"Series A Merger Consideration\"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3]"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001683607-26-000006","document":"wk-form4_1767835143.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683607/000168360726000006/wk-form4_1767835143.xml","form_type":"4"}},{"id":948745,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-01-06T21:08:03.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":1962,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1962,"derivative":{"exercise_price":772.76,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":1962},"source":{"system":"sec-edgar","filing":"0001683607-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168360726000004/edgardoc.xml","form_type":"4"}},{"id":948744,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:08:03.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1703,"source":{"system":"sec-edgar","filing":"0001683607-26-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168360726000004/edgardoc.xml","form_type":"4"}},{"id":955257,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2026-01-02T21:06:43.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":967,"price":38.7418,"value":37463.3206,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":73132,"source":{"system":"sec-edgar","filing":"0001683607-26-000002","document":"wk-form4_1767388000.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000168360726000002/wk-form4_1767388000.xml","form_type":"4"}},{"id":990648,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-11-24T21:05:34.000Z","date":"2025-11-20","kind":"exercise","planned":true,"acquired":false,"shares":760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant."}],"balance_after":756,"derivative":{"exercise_price":371.4,"expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":760},"source":{"system":"sec-edgar","filing":"0001683607-25-000006","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168360725000006/edgardoc.xml","form_type":"4"}},{"id":990647,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-24T21:05:34.000Z","date":"2025-11-20","kind":"sale","planned":true,"acquired":false,"shares":760,"price":750,"value":570000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025."}],"balance_after":1548,"source":{"system":"sec-edgar","filing":"0001683607-25-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168360725000006/edgardoc.xml","form_type":"4"}},{"id":990646,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-24T21:05:34.000Z","date":"2025-11-20","kind":"exercise","planned":true,"acquired":true,"shares":760,"price":371.4,"value":282264.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025."}],"balance_after":2308,"source":{"system":"sec-edgar","filing":"0001683607-25-000006","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000168360725000006/edgardoc.xml","form_type":"4"}},{"id":1030614,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2025-09-30T20:54:16.000Z","date":"2025-09-30","kind":"grant","planned":false,"acquired":true,"shares":1047,"price":35.7872,"value":37469.1984,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":72165,"source":{"system":"sec-edgar","filing":"0001683607-25-000004","document":"wk-form4_1759265653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000168360725000004/wk-form4_1759265653.xml","form_type":"4"}},{"id":1099342,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2025-06-30T21:04:29.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":1064,"price":35.2395,"value":37494.828,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":71118,"source":{"system":"sec-edgar","filing":"0001802768-25-000075","document":"wk-form4_1751317462.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000075/wk-form4_1751317462.xml","form_type":"4"}},{"id":1106321,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T21:03:23.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":11100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders."}],"balance_after":11100,"derivative":{"exercise_price":21.31,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":11100},"source":{"system":"sec-edgar","filing":"0001610618-25-000062","document":"wk-form4_1750280597.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683607/000161061825000062/wk-form4_1750280597.xml","form_type":"4"}},{"id":1149290,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2025-05-14T21:04:55.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":7614,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":70054,"source":{"system":"sec-edgar","filing":"0001802768-25-000045","document":"wk-form4_1747256688.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000045/wk-form4_1747256688.xml","form_type":"4"}},{"id":1186540,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2025-04-01T21:46:45.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":1141,"price":32.8658,"value":37499.8778,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":62440,"source":{"system":"sec-edgar","filing":"0001802768-25-000017","document":"wk-form4_1743543999.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000017/wk-form4_1743543999.xml","form_type":"4"}},{"id":1312104,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-01-06T21:04:09.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":1958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1958,"derivative":{"exercise_price":719.37,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":1958},"source":{"system":"sec-edgar","filing":"0001968202-25-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820225000002/edgardoc.xml","form_type":"4"}},{"id":1312103,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-06T21:04:09.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1548,"source":{"system":"sec-edgar","filing":"0001968202-25-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820225000002/edgardoc.xml","form_type":"4"}},{"id":1318747,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2025-01-02T21:29:17.000Z","date":"2024-12-31","kind":"grant","planned":false,"acquired":true,"shares":1503,"price":24.9416,"value":37487.2248,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":61299,"source":{"system":"sec-edgar","filing":"0001802768-25-000006","document":"wk-form4_1735853350.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000006/wk-form4_1735853350.xml","form_type":"4"}},{"id":1325428,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-19T23:17:13.000Z","date":"2024-12-17","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of December 17, 2024."}],"balance_after":16000,"derivative":{"exercise_price":22.81,"expiration_date":"2034-12-16","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001610618-24-000150","document":"wk-form4_1734650227.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683607/000161061824000150/wk-form4_1734650227.xml","form_type":"4"}},{"id":1397915,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-09-30T21:08:48.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":1342,"price":27.9249,"value":37475.2158,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"1. Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":59796,"source":{"system":"sec-edgar","filing":"0001802768-24-000055","document":"wk-form4_1727730521.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276824000055/wk-form4_1727730521.xml","form_type":"4"}},{"id":1430220,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-08-19T20:02:05.000Z","date":"2024-08-15","kind":"exercise","planned":true,"acquired":false,"shares":756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant."}],"balance_after":1516,"derivative":{"exercise_price":371.4,"expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":756},"source":{"system":"sec-edgar","filing":"0001968202-24-000123","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000123/edgardoc.xml","form_type":"4"}},{"id":1430219,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-19T20:02:05.000Z","date":"2024-08-15","kind":"sale","planned":true,"acquired":false,"shares":756,"price":1170,"value":884520.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024."}],"balance_after":1382,"source":{"system":"sec-edgar","filing":"0001968202-24-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000123/edgardoc.xml","form_type":"4"}},{"id":1430218,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-19T20:02:05.000Z","date":"2024-08-15","kind":"exercise","planned":true,"acquired":true,"shares":756,"price":371.4,"value":280778.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024."}],"balance_after":2138,"source":{"system":"sec-edgar","filing":"0001968202-24-000123","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000123/edgardoc.xml","form_type":"4"}},{"id":1441597,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-08-05T20:05:41.000Z","date":"2024-08-02","kind":"exercise","planned":true,"acquired":false,"shares":756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant."}],"balance_after":2272,"derivative":{"exercise_price":371.4,"expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":756},"source":{"system":"sec-edgar","filing":"0001883850-24-000041","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000041/edgardoc.xml","form_type":"4"}},{"id":1441596,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:05:41.000Z","date":"2024-08-02","kind":"sale","planned":true,"acquired":false,"shares":756,"price":1115,"value":842940.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024."}],"balance_after":1382,"source":{"system":"sec-edgar","filing":"0001883850-24-000041","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000041/edgardoc.xml","form_type":"4"}},{"id":1441595,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-05T20:05:41.000Z","date":"2024-08-02","kind":"exercise","planned":true,"acquired":true,"shares":756,"price":371.4,"value":280778.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024."}],"balance_after":2138,"source":{"system":"sec-edgar","filing":"0001883850-24-000041","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000041/edgardoc.xml","form_type":"4"}},{"id":1451210,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-19T20:55:11.000Z","date":"2024-07-18","kind":"grant","planned":false,"acquired":true,"shares":2125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2025 annual meeting of stockholders."}],"balance_after":2125,"derivative":{"exercise_price":12.64,"expiration_date":"2034-07-17","underlying":"Common Stock","underlying_shares":2125},"source":{"system":"sec-edgar","filing":"0001610618-24-000106","document":"wk-form4_1721422504.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683607/000161061824000106/wk-form4_1721422504.xml","form_type":"4"}},{"id":1467285,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-06-28T21:09:50.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":1399,"price":26.7998,"value":37492.9202,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":58454,"source":{"system":"sec-edgar","filing":"0001802768-24-000040","document":"wk-form4_1719608984.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276824000040/wk-form4_1719608984.xml","form_type":"4"}},{"id":1470035,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-06-25T20:41:00.000Z","date":"2024-06-24","kind":"exercise","planned":true,"acquired":false,"shares":756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant."}],"balance_after":3028,"derivative":{"exercise_price":371.4,"expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":756},"source":{"system":"sec-edgar","filing":"0001883850-24-000037","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000037/edgardoc.xml","form_type":"4"}},{"id":1470034,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-25T20:41:00.000Z","date":"2024-06-24","kind":"sale","planned":true,"acquired":false,"shares":756,"price":1062,"value":802872.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024."}],"balance_after":1382,"source":{"system":"sec-edgar","filing":"0001883850-24-000037","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000037/edgardoc.xml","form_type":"4"}},{"id":1470033,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-25T20:41:00.000Z","date":"2024-06-24","kind":"exercise","planned":true,"acquired":true,"shares":756,"price":371.4,"value":280778.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024."}],"balance_after":2138,"source":{"system":"sec-edgar","filing":"0001883850-24-000037","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000037/edgardoc.xml","form_type":"4"}},{"id":1485051,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-06-10T20:09:42.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":9293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":57055,"source":{"system":"sec-edgar","filing":"0001802768-24-000025","document":"wk-form4_1718050174.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276824000025/wk-form4_1718050174.xml","form_type":"4"}},{"id":1487621,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-06-07T20:06:29.000Z","date":"2024-06-05","kind":"exercise","planned":true,"acquired":false,"shares":827,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":380.95,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":827},"source":{"system":"sec-edgar","filing":"0001883850-24-000027","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000027/edgardoc.xml","form_type":"4"}},{"id":1487620,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T20:06:29.000Z","date":"2024-06-05","kind":"sale","planned":true,"acquired":false,"shares":827,"price":1011,"value":836097.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024."}],"balance_after":1382,"source":{"system":"sec-edgar","filing":"0001883850-24-000027","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000027/edgardoc.xml","form_type":"4"}},{"id":1487619,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T20:06:29.000Z","date":"2024-06-05","kind":"exercise","planned":true,"acquired":true,"shares":827,"price":380.95,"value":315045.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024."}],"balance_after":2209,"source":{"system":"sec-edgar","filing":"0001883850-24-000027","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000027/edgardoc.xml","form_type":"4"}},{"id":1553795,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-04-02T21:28:46.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":1240,"price":30.2283,"value":37483.092,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":47762,"source":{"system":"sec-edgar","filing":"0001802768-24-000016","document":"wk-form4_1712093313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276824000016/wk-form4_1712093313.xml","form_type":"4"}},{"id":1620742,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-02-26T21:07:53.000Z","date":"2024-02-26","kind":"exercise","planned":false,"acquired":false,"shares":854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":391.92,"expiration_date":"2026-09-09","underlying":"Common Stock","underlying_shares":854},"source":{"system":"sec-edgar","filing":"0001968202-24-000074","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000074/edgardoc.xml","form_type":"4"}},{"id":1620741,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-26T21:07:53.000Z","date":"2024-02-26","kind":"sale","planned":false,"acquired":false,"shares":854,"price":979.25,"value":836279.5,"ownership":{"direct":true},"balance_after":1382,"source":{"system":"sec-edgar","filing":"0001968202-24-000074","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000074/edgardoc.xml","form_type":"4"}},{"id":1620740,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-26T21:07:53.000Z","date":"2024-02-26","kind":"exercise","planned":false,"acquired":true,"shares":854,"price":391.92,"value":334699.68,"ownership":{"direct":true},"balance_after":2236,"source":{"system":"sec-edgar","filing":"0001968202-24-000074","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000074/edgardoc.xml","form_type":"4"}},{"id":1665795,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-01-31T21:52:52.000Z","date":"2024-01-30","kind":"exercise","planned":true,"acquired":false,"shares":827,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":827,"derivative":{"exercise_price":380.95,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":827},"source":{"system":"sec-edgar","filing":"0001883850-24-000010","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000010/edgardoc.xml","form_type":"4"}},{"id":1665794,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T21:52:52.000Z","date":"2024-01-30","kind":"sale","planned":true,"acquired":false,"shares":827,"price":959,"value":793093.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."}],"balance_after":1382,"source":{"system":"sec-edgar","filing":"0001883850-24-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000010/edgardoc.xml","form_type":"4"}},{"id":1665793,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T21:52:52.000Z","date":"2024-01-30","kind":"exercise","planned":true,"acquired":true,"shares":827,"price":380.95,"value":315045.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."}],"balance_after":2209,"source":{"system":"sec-edgar","filing":"0001883850-24-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000010/edgardoc.xml","form_type":"4"}},{"id":1689469,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-01-04T21:11:19.000Z","date":"2024-01-02","kind":"grant","planned":true,"acquired":true,"shares":1607,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1607,"derivative":{"exercise_price":888.34,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":1607},"source":{"system":"sec-edgar","filing":"0001968202-24-000027","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000027/edgardoc.xml","form_type":"4"}},{"id":1689468,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-01-04T21:11:19.000Z","date":"2024-01-03","kind":"exercise","planned":true,"acquired":false,"shares":826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":1654,"derivative":{"exercise_price":380.95,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":826},"source":{"system":"sec-edgar","filing":"0001968202-24-000027","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000027/edgardoc.xml","form_type":"4"}},{"id":1689467,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-04T21:11:19.000Z","date":"2024-01-03","kind":"sale","planned":true,"acquired":false,"shares":826,"price":914,"value":754964.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."}],"balance_after":1382,"source":{"system":"sec-edgar","filing":"0001968202-24-000027","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000027/edgardoc.xml","form_type":"4"}},{"id":1689466,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-04T21:11:19.000Z","date":"2024-01-03","kind":"exercise","planned":true,"acquired":true,"shares":826,"price":380.95,"value":314664.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."}],"balance_after":2208,"source":{"system":"sec-edgar","filing":"0001968202-24-000027","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000027/edgardoc.xml","form_type":"4"}},{"id":1689465,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-04T21:11:19.000Z","date":"2024-01-02","kind":"grant","planned":true,"acquired":true,"shares":135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1382,"source":{"system":"sec-edgar","filing":"0001968202-24-000027","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000027/edgardoc.xml","form_type":"4"}},{"id":1698001,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-12-29T22:11:46.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":1353,"price":27.711,"value":37492.983,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":46522,"source":{"system":"sec-edgar","filing":"0001802768-23-000035","document":"wk-form4_1703887896.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276823000035/wk-form4_1703887896.xml","form_type":"4"}},{"id":1711602,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-12-14T21:07:40.000Z","date":"2023-12-13","kind":"exercise","planned":true,"acquired":false,"shares":610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":376.69,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":610},"source":{"system":"sec-edgar","filing":"0001883850-23-000099","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000099/edgardoc.xml","form_type":"4"}},{"id":1711601,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T21:07:40.000Z","date":"2023-12-13","kind":"sale","planned":true,"acquired":false,"shares":610,"price":870,"value":530700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."}],"balance_after":1247,"source":{"system":"sec-edgar","filing":"0001883850-23-000099","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000099/edgardoc.xml","form_type":"4"}},{"id":1711600,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T21:07:40.000Z","date":"2023-12-13","kind":"exercise","planned":true,"acquired":true,"shares":610,"price":376.69,"value":229780.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."}],"balance_after":1857,"source":{"system":"sec-edgar","filing":"0001883850-23-000099","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000099/edgardoc.xml","form_type":"4"}},{"id":1767699,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-10-03T20:23:45.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":1384,"price":27.0775,"value":37475.26,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":45169,"source":{"system":"sec-edgar","filing":"0001209191-23-051471","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123051471/doc4.xml","form_type":"4"}},{"id":1799047,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-08-23T20:03:08.000Z","date":"2023-08-21","kind":"exercise","planned":true,"acquired":false,"shares":853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":854,"derivative":{"exercise_price":391.92,"expiration_date":"2026-09-09","underlying":"Common Stock","underlying_shares":853},"source":{"system":"sec-edgar","filing":"0001968202-23-000022","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000022/edgardoc.xml","form_type":"4"}},{"id":1799046,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-23T20:03:08.000Z","date":"2023-08-21","kind":"sale","planned":true,"acquired":false,"shares":853,"price":829,"value":707137.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."}],"balance_after":1247,"source":{"system":"sec-edgar","filing":"0001968202-23-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000022/edgardoc.xml","form_type":"4"}},{"id":1799045,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-23T20:03:08.000Z","date":"2023-08-21","kind":"exercise","planned":true,"acquired":true,"shares":853,"price":391.92,"value":334307.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."}],"balance_after":2100,"source":{"system":"sec-edgar","filing":"0001968202-23-000022","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000022/edgardoc.xml","form_type":"4"}},{"id":1810328,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-08-11T20:13:25.000Z","date":"2023-08-10","kind":"exercise","planned":true,"acquired":false,"shares":853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":1707,"derivative":{"exercise_price":391.92,"expiration_date":"2026-09-09","underlying":"Common Stock","underlying_shares":853},"source":{"system":"sec-edgar","filing":"0001883850-23-000077","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000077/edgardoc.xml","form_type":"4"}},{"id":1810327,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T20:13:25.000Z","date":"2023-08-10","kind":"sale","planned":true,"acquired":false,"shares":853,"price":789,"value":673017.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."}],"balance_after":1247,"source":{"system":"sec-edgar","filing":"0001883850-23-000077","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000077/edgardoc.xml","form_type":"4"}},{"id":1810326,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T20:13:25.000Z","date":"2023-08-10","kind":"exercise","planned":true,"acquired":true,"shares":853,"price":391.92,"value":334307.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 11, 2023."}],"balance_after":2100,"source":{"system":"sec-edgar","filing":"0001883850-23-000077","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000077/edgardoc.xml","form_type":"4"}},{"id":1841156,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-06-30T13:12:31.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":1208,"price":31.0273,"value":37480.9784,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":43785,"source":{"system":"sec-edgar","filing":"0001209191-23-040237","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123040237/doc4.xml","form_type":"4"}},{"id":1844283,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-06-26T20:02:13.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":7747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":42577,"source":{"system":"sec-edgar","filing":"0001209191-23-039671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123039671/doc4.xml","form_type":"4"}},{"id":1845231,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T21:17:41.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2024 annual meeting of stockholders."}],"balance_after":42500,"derivative":{"exercise_price":1.17,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":42500},"source":{"system":"sec-edgar","filing":"0001610618-23-000063","document":"wf-form4_168755504603545.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683607/000161061823000063/wf-form4_168755504603545.xml","form_type":"4"}},{"id":1934053,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-03-31T20:38:27.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":1049,"price":35.7276,"value":37478.2524,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":34830,"source":{"system":"sec-edgar","filing":"0001209191-23-021880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123021880/doc4.xml","form_type":"4"}},{"id":1938449,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-03-27T20:43:29.000Z","date":"2023-03-24","kind":"exercise","planned":true,"acquired":false,"shares":1240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":2480,"derivative":{"exercise_price":380.95,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":1240},"source":{"system":"sec-edgar","filing":"0001883850-23-000064","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000064/edgardoc.xml","form_type":"4"}},{"id":1938448,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-27T20:43:29.000Z","date":"2023-03-24","kind":"sale","planned":true,"acquired":false,"shares":1240,"price":818,"value":1014320.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022."}],"balance_after":1247,"source":{"system":"sec-edgar","filing":"0001883850-23-000064","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000064/edgardoc.xml","form_type":"4"}},{"id":1938447,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-27T20:43:29.000Z","date":"2023-03-24","kind":"exercise","planned":true,"acquired":true,"shares":1240,"price":380.95,"value":472378.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 4, 2022."}],"balance_after":2487,"source":{"system":"sec-edgar","filing":"0001883850-23-000064","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000064/edgardoc.xml","form_type":"4"}},{"id":2029486,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-02-07T21:09:53.000Z","date":"2023-02-03","kind":"exercise","acquired":false,"shares":1021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":3720,"derivative":{"exercise_price":380.95,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":1021},"source":{"system":"sec-edgar","filing":"0001883850-23-000036","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000036/edgardoc.xml","form_type":"4"}},{"id":2029485,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-07T21:09:53.000Z","date":"2023-02-03","kind":"sale","acquired":false,"shares":1021,"price":779,"value":795359.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":1247,"source":{"system":"sec-edgar","filing":"0001883850-23-000036","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000036/edgardoc.xml","form_type":"4"}},{"id":2029484,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-07T21:09:53.000Z","date":"2023-02-03","kind":"exercise","acquired":true,"shares":1021,"price":380.95,"value":388949.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2268,"source":{"system":"sec-edgar","filing":"0001883850-23-000036","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000036/edgardoc.xml","form_type":"4"}},{"id":2064247,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-05T21:21:59.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":1929,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1929,"derivative":{"exercise_price":725.89,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":1929},"source":{"system":"sec-edgar","filing":"0001883850-23-000020","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000020/edgardoc.xml","form_type":"4"}},{"id":2064246,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T21:21:59.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1247,"source":{"system":"sec-edgar","filing":"0001883850-23-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000020/edgardoc.xml","form_type":"4"}},{"id":2072752,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-01-03T22:09:21.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":943,"price":39.7613,"value":37494.9059,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":33781,"source":{"system":"sec-edgar","filing":"0001209191-23-000322","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123000322/doc4.xml","form_type":"4"}},{"id":2090480,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-12T21:35:30.000Z","date":"2022-12-08","kind":"exercise","acquired":false,"shares":218,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":4741,"derivative":{"exercise_price":380.95,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":218},"source":{"system":"sec-edgar","filing":"0001883850-22-000108","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000108/edgardoc.xml","form_type":"4"}},{"id":2090479,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-12T21:35:30.000Z","date":"2022-12-08","kind":"sale","acquired":false,"shares":218,"price":779,"value":169822.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":1082,"source":{"system":"sec-edgar","filing":"0001883850-22-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000108/edgardoc.xml","form_type":"4"}},{"id":2090478,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-12T21:35:30.000Z","date":"2022-12-08","kind":"exercise","acquired":true,"shares":218,"price":380.95,"value":83047.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":1300,"source":{"system":"sec-edgar","filing":"0001883850-22-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000108/edgardoc.xml","form_type":"4"}},{"id":2148740,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-09-30T20:29:13.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":913,"price":41.0629,"value":37490.4277,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":32838,"source":{"system":"sec-edgar","filing":"0001209191-22-051644","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919122051644/doc4.xml","form_type":"4"}},{"id":2161692,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-09-12T20:31:44.000Z","date":"2022-09-08","kind":"exercise","acquired":false,"shares":1279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":2560,"derivative":{"exercise_price":391.92,"expiration_date":"2026-09-09","underlying":"Common Stock","underlying_shares":1279},"source":{"system":"sec-edgar","filing":"0001883850-22-000068","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000068/edgardoc.xml","form_type":"4"}},{"id":2161691,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-09-12T20:31:44.000Z","date":"2022-09-08","kind":"exercise","acquired":false,"shares":1279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":3839,"derivative":{"exercise_price":391.92,"expiration_date":"2026-09-09","underlying":"Common Stock","underlying_shares":1279},"source":{"system":"sec-edgar","filing":"0001883850-22-000068","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000068/edgardoc.xml","form_type":"4"}},{"id":2161690,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-09-12T20:31:44.000Z","date":"2022-09-09","kind":"exercise","acquired":false,"shares":609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":610,"derivative":{"exercise_price":376.69,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":609},"source":{"system":"sec-edgar","filing":"0001883850-22-000068","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000068/edgardoc.xml","form_type":"4"}},{"id":2161689,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-12T20:31:44.000Z","date":"2022-09-09","kind":"sale","acquired":false,"shares":609,"price":741,"value":451269.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":1082,"source":{"system":"sec-edgar","filing":"0001883850-22-000068","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000068/edgardoc.xml","form_type":"4"}},{"id":2161688,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-12T20:31:44.000Z","date":"2022-09-09","kind":"exercise","acquired":true,"shares":609,"price":376.69,"value":229404.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":1691,"source":{"system":"sec-edgar","filing":"0001883850-22-000068","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000068/edgardoc.xml","form_type":"4"}},{"id":2161687,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-12T20:31:44.000Z","date":"2022-09-08","kind":"sale","acquired":false,"shares":1279,"price":686.99,"value":878660.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":1082,"source":{"system":"sec-edgar","filing":"0001883850-22-000068","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000068/edgardoc.xml","form_type":"4"}},{"id":2161686,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-12T20:31:44.000Z","date":"2022-09-08","kind":"exercise","acquired":true,"shares":1279,"price":391.92,"value":501265.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2361,"source":{"system":"sec-edgar","filing":"0001883850-22-000068","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000068/edgardoc.xml","form_type":"4"}},{"id":2161685,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-12T20:31:44.000Z","date":"2022-09-08","kind":"sale","acquired":false,"shares":1279,"price":705,"value":901695.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 1,279 shares of Company stock on September 8, 2022 at prices ranging from $705.00 to $705.06. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 8, 2022 at each separate price."}],"balance_after":1082,"source":{"system":"sec-edgar","filing":"0001883850-22-000068","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000068/edgardoc.xml","form_type":"4"}},{"id":2161684,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-12T20:31:44.000Z","date":"2022-09-08","kind":"exercise","acquired":true,"shares":1279,"price":391.92,"value":501265.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2361,"source":{"system":"sec-edgar","filing":"0001883850-22-000068","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000068/edgardoc.xml","form_type":"4"}},{"id":2218762,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-06-30T10:55:16.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":903,"price":41.5203,"value":37492.8309,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500."}],"balance_after":31925,"source":{"system":"sec-edgar","filing":"0001209191-22-039877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919122039877/doc4.xml","form_type":"4"}},{"id":2222076,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T21:31:45.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2023 annual meeting of stockholders."}],"balance_after":28000,"derivative":{"exercise_price":0.53,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001610618-22-000056","document":"wf-form4_165610629103916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683607/000161061822000056/wf-form4_165610629103916.xml","form_type":"4"}},{"id":2222135,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-06-24T20:57:49.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":6328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":31022,"source":{"system":"sec-edgar","filing":"0000899243-22-024042","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000089924322024042/doc4.xml","form_type":"4"}},{"id":2299673,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-04-11T20:38:35.000Z","date":"2022-04-07","kind":"exercise","acquired":false,"shares":1240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":4959,"derivative":{"exercise_price":380.95,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":1240},"source":{"system":"sec-edgar","filing":"0001708138-22-000038","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813822000038/edgardoc.xml","form_type":"4"}},{"id":2299672,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":34480,"kind":"person","name":"Bassler Bonnie L","position":1,"cik":"0001683607","reported_name":"Bassler Bonnie L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-11T20:38:35.000Z","date":"2022-04-07","kind":"sale","acquired":false,"shares":1240,"price":725,"value":899000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":1082,"source":{"system":"sec-edgar","filing":"0001708138-22-000038","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813822000038/edgardoc.xml","form_type":"4"}}],"next_cursor":"2022-04-11T20:38:35.000000Z,2299672"}